Oncolytic (replication-competent) adenoviruses as anticancer agents
- PMID: 20132057
- DOI: 10.1517/14712590903559822
Oncolytic (replication-competent) adenoviruses as anticancer agents
Abstract
Importance of the field: Whilst therapies for neoplasies have advanced tremendously in the last few decades, there is still a need for new anti-cancer treatments. One option is genetically-engineered oncolytic adenovirus (Ad) 'vectors'. These kill cancer cells via the viral replication cycle, and amplify the anti-tumor effect by producing progeny virions able to infect neighboring tumor cells.
Areas covered in this review: We provide a description of basic Ad biology and summarize the literature for oncolytic Ads from 1996 to the present.
What the reader will gain: An overall view of oncolytic Ads, the merits and drawbacks of the various features of these vectors, and obstacles to further development and future directions for research.
Take home message: Ads are attractive for gene therapy because they are relatively innocuous, easy to produce in large quantities, genetically stable, and easy to manipulate. A variety of have been constructed and tested, in pre-clinical and clinical experiments. Oncolytic Ads proved to be remarkably safe; no dose-limiting toxicity was observed in any clinical trial, and the maximum tolerated dose was not reached. At present, the major challenge for researchers is to increase the efficacy of the vectors, and to incorporate oncolytic virotherapy into existing treatment protocols.
Similar articles
-
Oncolytic adenoviruses - selective retargeting to tumor cells.Oncogene. 2005 Nov 21;24(52):7775-91. doi: 10.1038/sj.onc.1209044. Oncogene. 2005. PMID: 16299537 Review.
-
Clinical development directions in oncolytic viral therapy.Cancer Gene Ther. 2011 May;18(5):305-17. doi: 10.1038/cgt.2011.7. Epub 2011 Mar 25. Cancer Gene Ther. 2011. PMID: 21436867 Review.
-
Oncolytic adenoviral therapy for glioblastoma multiforme.Neurosurg Focus. 2006 Apr 15;20(4):E19. Neurosurg Focus. 2006. PMID: 16709024 Review.
-
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.Gene Ther. 2006 Jul;13(13):1010-20. doi: 10.1038/sj.gt.3302759. Epub 2006 Mar 9. Gene Ther. 2006. PMID: 16525479
-
Development of transcriptionally regulated oncolytic adenoviruses.Oncogene. 2005 Nov 21;24(52):7763-74. doi: 10.1038/sj.onc.1209048. Oncogene. 2005. PMID: 16299536 Review.
Cited by
-
Poly-Gamma-Glutamic Acid (γ-PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies.Molecules. 2018 Oct 8;23(10):2565. doi: 10.3390/molecules23102565. Molecules. 2018. PMID: 30297641 Free PMC article.
-
Directed adenovirus evolution using engineered mutator viral polymerases.Nucleic Acids Res. 2011 Mar;39(5):e30. doi: 10.1093/nar/gkq1258. Epub 2010 Dec 7. Nucleic Acids Res. 2011. PMID: 21138963 Free PMC article.
-
Innate immunity to adenovirus.Hum Gene Ther. 2014 Apr;25(4):265-84. doi: 10.1089/hum.2014.001. Epub 2014 Apr 8. Hum Gene Ther. 2014. PMID: 24512150 Free PMC article. Review.
-
Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.Mol Ther. 2014 Aug;22(8):1504-1517. doi: 10.1038/mt.2014.80. Epub 2014 May 5. Mol Ther. 2014. PMID: 24791939 Free PMC article.
-
High-level expression by tissue/cancer-specific promoter with strict specificity using a single-adenoviral vector.Nucleic Acids Res. 2011 Jan;39(2):e7. doi: 10.1093/nar/gkq966. Epub 2010 Nov 4. Nucleic Acids Res. 2011. PMID: 21051352 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
